key: cord-0861418-x7wn00pn
authors: Marjot, Thomas; Moon, Andrew M.; Cook, Jonathan A.; Abd-Elsalam, Sherief; Aloman, Costica; Armstrong, Matthew J.; Pose, Elisa; Brenner, Erica J.; Cargill, Tamsin; Catana, Maria-Andreea; Dhanasekaran, Renumathy; Eshraghian, Ahad; García-Juárez, Ignacio; Gill, Upkar S.; Jones, Patricia D.; Kennedy, James; Marshall, Aileen; Matthews, Charmaine; Mells, George; Mercer, Carolyn; Perumalswami, Ponni V.; Avitabile, Emma; Qi, Xialong; Su, Feng; Ufere, Nneka N.; Wong, Yu Jun; Zheng, Ming-Hua; Barnes, Eleanor; Barritt, Alfred S.; Webb, Gwilym J.
title: Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study
date: 2020-10-06
journal: J Hepatol
DOI: 10.1016/j.jhep.2020.09.024
sha: 9d598fab03c82bedb9eb51b1a6c680e7ae655437
doc_id: 861418
cord_uid: x7wn00pn

BACKGROUND: Chronic liver disease (CLD) and cirrhosis are associated with immune dysregulation leading to concerns that these patients may be at risk of adverse outcomes following SARS-CoV-2 infection. However, the impact of COVID-19 among patients with pre-existing liver disease remains ill-defined. METHODS: Data for CLD patients with SARS-CoV-2 were collected by two international registries. Comparisons were made with non-CLD patients with SARS-CoV-2 from a UK hospital network. RESULTS: Between 25th March and 8th July 2020, 745 CLD patients were reported from 29 countries including 386 with cirrhosis and 359 without. Mortality was 32% in patients with cirrhosis compared with 8% in those without (p<0.001). Mortality in cirrhosis patients increased according to Child-Turcotte-Pugh class (CTP-A (19%), CTP-B (35%), CTP-C (51%)) and the main cause of death was respiratory failure (71%). After adjusting for baseline characteristics, factors associated with death in the total CLD cohort were age (OR 1.02; 1.01–1.04), CTP-A (OR 1.90; 1.03–3.52), CTP-B (OR 4.14; 2.4–7.65), CTP-C cirrhosis (OR 9.32; 4.80–18.08) and alcohol related liver disease (ALD) (OR 1.79; 1.03–3.13). When comparing CLD versus non-CLD (n=620) in propensity-score-matched analysis there were significant increases in mortality with CTP-B +20.0% (8.8%–31.3%) and CTP-C cirrhosis +38.1% (27.1%–49.2%). Acute hepatic decompensation occurred in 46% of patients with cirrhosis, of which 21% had no respiratory symptoms. 50% of those with hepatic decompensation had acute-on-chronic liver failure. CONCLUSIONS: This is the largest reported cohort of CLD and cirrhosis patients with SARS-CoV-2 infection to date. We demonstrate that baseline liver disease stage and ALD are independent risk factor for death from COVID-19. These data have important implications for the risk stratification of patients with CLD across the globe during the COVID-19 pandemic.

Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has emerged as a major international public health crisis.

Whilst medical comorbidities including hypertension, chronic lung disease and heart disease [1] have been implicated as risk factors for poor outcomes following SARS-CoV-2 infection, the impact of underlying chronic liver disease (CLD) remains incompletely defined. The global burden of CLD is vast, with cirrhosis now estimated to affect 112 million people worldwide resulting in 2 million deaths per year through hepatic decompensation and hepatocellular carcinoma (HCC) [2, 3] . Cirrhosis is characterised by immune dysregulation leading to concerns that these patients may be at increased risk for complications following SARS-CoV-2 infection [4] . International guidelines have tended to advocate for enhanced physical distancing for patients with cirrhosis, however this must be balanced against the risks of delayed or altered standard of care for this vulnerable patient group [5] . A precise understanding of outcomes from COVID-19 in CLD patients across the entire spectrum of liver disease severity is therefore urgently required in order to allow accurate risk stratification.

High mortality rates from COVID-19 among patients with cirrhosis have been reported in several recently published series. However, these studies were limited to small cohorts of fewer than 50 cirrhosis patients, often lacked a comparison cohort without CLD, or used hospital coding data that is prone to misclassifying liver disease severity [6] [7] [8] [9] [10] [11] . Furthermore, these studies were restricted to single geographical regions limiting generalizability particularly in light of the wide global variability in liver disease aetiology [12] .

In the present work, we report on the largest cohort of patients with CLD and laboratory proven SARS-CoV-2 infection to date, collected through two collaborative, large-scale international reporting registries. We also offer comparisons with a contemporaneous cohort of patients without CLD testing positive for SARS-CoV-2 at a large hospital network in the United Kingdom (UK).

J o u r n a l P r e -p r o o f 8 

We conducted a multinational cohort study using an open online reporting form for patients with laboratory-confirmed SARS-CoV-2 and CLD. Data were collected between 25 th March 2020 and 8th July 2020 through two collaborating online registries (SECURE-cirrhosis co-ordinated by University of North Carolina, Chapel Hill, USA and COVID-Hep.net co-ordinated by University of Oxford and supported by The European Association for the Study of the Liver). The registries were widely advertised through the communication channels of multiple endorsing gastroenterology and hepatology societies, direct emails to hepatology providers, and through social media. Submitting clinicians were asked to complete a case report form of clinical data at the end of their patient's disease course, defined as resolution of clinical signs of COVID-19, discharge from hospital, or death. A copy of the data collection tool is available as a Supplementary appendix and was identical for both registries.

To provide a comparison cohort of patients without CLD, data were extracted using an identical data collection tool from electronic patient records of consecutive patients testing positive for SARS-CoV-2 over the same time period at Oxford University Hospitals NHS Foundation Trust (OUHFT), an organisation of four hospitals in and around Oxford in the UK. Positive cases from OUHFT were defined as detection of SARS-CoV-2 by reverse transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal swabs. Cases of SARS-CoV-2 infection with CLD who were identified in the non-CLD cohort were incorporated in the CLD cohort. To minimise potential reporting bias, data extraction for the non-CLD cohort was performed by investigators blinded to the clinical characteristics and outcomes reported in CLD patients. All data for both CLD and non-CLD cohorts were uploaded real-time to the same secure, online, data capture tool [13] .

All submitted report forms for both CLD and non-CLD cohorts were manually reviewed to assess for data quality, completeness and inconsistencies and in some instances, submitting clinicians were contacted and asked to provide additional data where appropriate. 

All cases of laboratory-confirmed SARS-CoV-2 infection in patients with CLD aged >16yrs, from any location, and with any symptom profile or disease severity were included in the analysis. Cases were excluded if any of the following conditions were met: SARS-CoV-2 infection was not laboratory-confirmed, the submission was a duplicate, if hospitalisation status or mortality outcome was not known or not reported, or if the patient was not aged over 16 years at the time of diagnosis. The current study contains 152 cases included in a previously published preliminary analysis [14] .

Liver disease stage was categorized by the reporting clinician as CLD with or without cirrhosis.

Those with cirrhosis were then further sub-categorized by the reporting clinician according to Child-Turcotte-Pugh class (CTP-A, CTP-B, CTP-C). Throughout this paper the following terminology will be used to define the groups; CLD without cirrhosis, cirrhosis, total CLD cohort (CLD), and patients without liver disease (non-CLD).

Obesity was defined as a BMI of >30 kg/m 2 ; where data on BMI was unavailable obesity was assumed to be absent. For analysis of ethnicity, only white ethnicity (as the majority classification) as compared to other ethnicities was considered in analysis. For the non-CLD cohort, where ethnicity was not recorded, white ethnicity was assumed. [15] Acute hepatic decompensation was defined as one or more of new or worsening ascites, new or worsening hepatic encephalopathy, spontaneous bacterial peritonitis, and/or variceal haemorrhage. The EASL Chronic Liver Failure Consortium (CLIF-C) definitions were used to J o u r n a l P r e -p r o o f determine the presence of ACLF in patients with acute hepatic decompensation, and to calculate the CLIF-C organ failure score [16, 17] . Model for end stage liver disease (MELD) included serum sodium, creatinine, bilirubin and international normalised ratio (INR) [18] .

Patient factors and outcome are summarised for both cohorts by occurrence of mortality using standard summary statistic (number of events and percentage for binary and median and interquartile range for continuous measures). Univariable analysis of mortality by patient characteristics was performed using logistic regression. Multivariable comparisons of factors associated with death within cohorts were assessed using logistic regression. The Hosmer-Lemeshow goodness of fit test was calculated for the multivariable logistic regression. Only patients with data available for each reported data point (with the exceptions of values assumed with regard to obesity and ethnicity explained above) were used in multivariable analyses. For sensitivity analysis, models were repeated with either forwards or backwards stepwise selection as described. Fisher's exact test was used to compare proportions between two populations and the Chi squared test for trend was used to compare proportions between 3 or more groups. Exact (Clopper-Pearson) binomial confidence intervals were calculated when describing proportions.

Nominal statistical significance at 2-sided 5% level was adopted for comparison of outcomes.

To compare the effect of the liver disease stage on risk of death, propensity score 1:1 matched samples (using nearest neighbour approach) were constructed with death as the outcome and liver disease status as the treatment variable for each of CLD without cirrhosis, CTP-A, CTP-B, and CTP-C. Covariables included in the propensity score model were selected as those thought to be independently associated with mortality for those with SARS-COV-2 but unlikely to be greatly otherwise associated with CLD whilst also aiming to provide matched variance ratios of between 0.5-2.0. Given that the non-CLD cohort was UK-derived, we also performed an identical propensity score matched analysis including only UK CLD cases as a sensitivity analysis. Propensity score matching was performed using the teffects function in Stata. The average treatment effect on the treated (ATET) was calculated with robust Abaide-Imbeds standard errors [19] . All statistical analyses were conducted using Stata v15.1 (College Station, TX).

Receiver operating characteristic (ROC) curves were calculated, and the area under the curve (AUC) was evaluated to determine the score accuracy (c-statistic) of baseline CTP score, MELD, and CLIF-C organ failure score as predictors of mortality following SARS-CoV-2 in patients with cirrhosis.

The study sponsors had no role in the study design; collection, analysis, and interpretation of data, the writing of the report; and in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. ASB, EB, JAC, AMM, TM, and GJW had access to the dataset. AMM, TM, and GJW performed the analyses with support from JAC.

Chronic liver disease cohort Table 1) . Within the 745 total cases, 359 (48%) had CLD without cirrhosis and 386 (52%) had cirrhosis.

In patients with cirrhosis, baseline Child-Turcotte-Pugh (CTP) class was CTP-A 171 (44%), CTP-B 124 (32%) and CTP-C 91 (24%) ( Table 1) . Baseline model for end stage liver disease (MELD) score was known in 331 (86%) of patients with cirrhosis with median score of 12 (IQR [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .

Within the same time period, data were collected using an identical case report form for 643 consecutive patients testing positive for SARS-CoV-2 at OUHFT. After excluding those with a previous liver transplant (n=1), CLD (n=8), those where hospitalisation or mortality status was unknown (n=6), and cases <16 years old (n=8), a total of 620 non-CLD cases remained (Supplementary figure 1) . The non-CLD cohort differed significantly from the CLD cohort with regards to age, sex, ethnicity, smoking status, baseline serum creatinine, and rates of comorbidities including heart disease, diabetes mellitus, HCC and non-HCC malignancy

Data on presenting symptoms were available in 729 (98%) of CLD patients. There were no differences between CLD patients with and without cirrhosis in the proportion presenting with respiratory symptoms (80% v. 80%; p=0.853), gastrointestinal symptoms (21% v. 21%; p=0.928) and those who were asymptomatic (13% v. 14%; p=0.832). Data on presenting symptoms were available in 522/620 (84%) of non-CLD patients. Compared to non-CLD patients, those with CLD had comparable rates of respiratory symptoms (81% vs. 80%; p=0.774) but higher rates of gastrointestinal symptoms (12% vs. 21%; p<0.001) at presentation.

Data on the use of targeted antiviral therapy was available for 735/745 (99%) of the CLD cohort.

Targeted therapy was used in 315 (42%) of total CLD cases with the most frequently used agents being chloroquine/hydroxychloroquine 162 (22%), lopinovir/ritonavir 114 (15%), and interferonalpha 69 (9%) (Supplementary table 4) . The proportion of patients receiving any targeted antiviral therapy was significantly lower in those with cirrhosis compared to those with CLD without cirrhosis (33% v. 52%; p = <0.001).

Within the total CLD cohort 668 (90%) were hospitalised, 235 (32%) were judged to require ICU care, 177 (24%) were ultimately admitted to ICU, 132 (18%) received invasive ventilation, 32 (4%) commenced renal replacement therapy, and 150 (20%) died. When comparing CLD without cirrhosis, CTP-A, CTP-B, and CTP-C cirrhosis, there was no difference in rates of hospitalisation (p=0.690). However, there were significantly higher rates in requirement for ICU (p<0.001), admission to ICU (p<0.001), renal replacement therapy (p=0.002), and death (p=<0.001) with increasing liver disease severity (Fig. 2) . Fifty-eight patients in the total CLD cohort were declined ICU admission despite having severe enough disease and this was due to ICU being deemed inappropriate in 54 (93%) and lack of ICU availability in 4 (7%). cardiac-related in 6 (5%). The median age of death was 61 years (IQR 54-71) in those with cirrhosis and 68 years (IQR 53-80) in those without (Fig. 3) . In the total CLD cohort there were stepwise increments in the rates of mortality following hospitalisation, admission to ICU, and invasive ventilation ( Table 2 ). Case fatality rates after each of these stages in the COVID-19 disease course were also heavily influenced by baseline liver disease severity ( Table 2 ). The clinical course and final outcomes of patients with and without cirrhosis are graphically represented in (Fig. 4) . To assess the ability of scoring systems to predict mortality in cirrhosis patients following SARS-CoV-2 infection an area-under the curve (AUC) analysis was performed. The AUC of J o u r n a l P r e -p r o o f baseline CTP score, baseline MELD, and CLIF-C organ failure score were 0.65, 0.64, and 0.75 respectively (Supplementary figure 3) .

To further assess for an association between liver disease and mortality, propensity score matched models were constructed for each stage of chronic liver disease (CLD without cirrhosis, CTP-A, CTP-B, and CTP-C) compared to the non-CLD comparison cohort using the following variables: age in years, interactions with age, sex, COPD, diabetes mellitus, and heart disease. p<0.001) (Fig 5A) .

Given that our comparison cohort was UK-derived, we also performed an identical propensity infection we show that baseline liver disease severity is a major determinant of outcome. As the severity of liver disease progresses from CLD without cirrhosis through to each Child-Turcotte-Pugh class of cirrhosis we observed a stepwise increased risk for all major adverse outcomes including ICU requirement and death.

Whilst patients with CLD without cirrhosis appear to have a similar risk of mortality following SARS-CoV-2 infection to patients without liver disease, patients with cirrhosis have an elevated risk (Fig. 5) with a mortality of 32% observed in the current study. Furthermore, in contrast to CLD patients without cirrhosis who display a striking age-related gradient for mortality with the highest risk of death in the 8th decade of life, mortality in patients with cirrhosis was more evenly distributed across age categories including a high mortality rate (31%) in those under 40 years (Fig. 3) . Our observed mortality rate in cirrhosis is comparable to the rates reported in recently published smaller studies in Northern Italy [8] (34%, n=50) and North America [7] (30%, n=36). Despite modest sample sizes, the former study showed higher mortality in cirrhosis patients with SARS-CoV-2 compared with bacterial infection (34% v. 17%; p=0.03), and the latter study demonstrated a trend towards increased mortality in hospitalised cirrhosis patients with COVID-19 compared to those without (30% v. 20%; p=0.11). Our observed rates of mortality in cirrhosis patients with COVID-19 (32%) also far exceeded that previously reported in hospitalised patients with cirrhosis in the era preceding COVID-19 (5-8%) [20, 21] , and in patients with cirrhosis admitted with influenza (18%) [22] . Furthermore, using propensity score matched analysis we demonstrate an incremental rise in the risk of death with each liver disease stage compared to a contemporaneous UK cohort of patients without CLD testing positive for SARS-CoV-2. These trends remain after restricting the analysis to CLD patients from the UK, including a statistically significant increased risk of death with CTP-B and CTP-C cirrhosis.

SARS-CoV-2 infection in patients with cirrhosis therefore appears to be a particularly lethal combination and represents the coming together of biological processes characterised by immune dysregulation in the context of viral infection and disordered coagulation.

In the current study, the predominant cause of death was COVID-19 lung injury, with only 19% of mortality in the patients with cirrhosis accounted for by liver-related complications. This implicates liver dysfunction as a potential driver of ongoing lung injury. Indeed, the significance of hepatic dysfunction in patients with bacterial chest sepsis is well recognized, with the presence of CLD already integrated into validated prognostic scoring systems for community acquired pneumonia [23, 24] . The mechanisms for enhanced respiratory compromise in CLD patients with SARS-CoV-2 require further investigation but may include altered pulmonary dynamics through worsening ascites or encephalopathy, immune dysfunction in viral infection, increased burden of venous thromboembolic disease, and coexisting lung disease (e.g. hepatopulmonary syndrome, portopulmonary hypertension, or hepatic hydrothorax).

Although baseline CTP score, baseline MELD, and CLIF-C organ failure score were all significantly associated with mortality, their ability to effectively discriminate those who survived or died following SARS-CoV-2 infection was limited (AUROC of 0.65, 0.64, and 0.75 respectively) (Supplementary figure 3) . However, Patients with advanced liver disease did have a particularly poor prognosis following SARS-CoV-2 infection with diminishing chances of recovery as they moved through the disease course. Only 46% of hospitalised patients with CTP-C cirrhosis survived, and this proportion dropped to 21% in those admitted to ICU and further still to 10% in those receiving invasive ventilation. These findings have important prognostic implications and highlight the need for careful monitoring of patients with cirrhosis throughout their hospital admission. Our data will also help inform clinical decisions regarding both the escalation of care to ICU and the use of COVID-19 palliative care guidelines in patients with advanced liver disease who undergo rapid inpatient clinical deterioration [25] . The high mortality in cirrhosis patients should also prompt consideration of novel targeted therapies such as dexamethasone with proven efficacy in hospitalized patients with COVID-19. However, our data show that cirrhosis patients are significantly less likely to received targeted antiviral therapy than CLD patients without cirrhosis which may reflect clinician concerns regarding the safety profile of various agents currently in development (Supplementary table 4) . This highlights the importance of carefully evaluating drug hepatotoxicity during COVID-19 clinical trials to ensure that cirrhosis patients are not unnecessarily denied potentially disease modifying treatments [26] .

For patients with cirrhosis, navigating through the COVID-19 pandemic is extremely challenging. In light of our data, which links liver disease severity with death following SARS-CoV-2 infection, a careful balance must be struck between protecting these patients from exposure to the virus whilst striving to deliver gold-standard treatment. The approach to each patient will be guided by individual risk, institutional resources and the local burden of COVID-19, however resumption of hepatology services wherever possible in order to prevent liver disease progression may ultimately represent the best strategy to protect patients from poor outcomes following future SARS-CoV-2 infection. The association between liver disease and adverse COVID-19 outcomes is also evidenced by recent findings from our registries which show that restoring hepatic function by liver transplantation in patients with decompensated cirrhosis returns the risk of mortality back to that of the general population [27] .

SARS-CoV-2 infection in patients with cirrhosis also appears to precipitate marked deterioration in liver function with high rates of acute hepatic decompensation (46%) observed in our cohort.

Importantly, 22% of those with acute hepatic decompensation did not have respiratory symptoms typical of COVID-19 at the time of diagnosis, thus highlighting the importance of maintaining a low threshold for SARS-CoV-2 testing in patients presenting with complications of cirrhosis.

The mechanisms by which SARS-CoV-2 infection causes hepatic dysfunction requires further exploration. Direct infection of liver cell types including cholangiocytes [28, 29] and hepatocytes [30] has been suggested, but the latter requires confirmatory testing since single cell RNA sequencing has shown relatively sparse hepatocyte expression of the receptors necessary for viral uptake [31] . However, given the profound multi-systemic involvement of COVID-19, particularly in the severe and critical forms of disease, liver injury is likely to be multifactorial with contributions from systemic inflammation, intrahepatic immune activation, microvascular thrombosis, perturbations of the gut-liver-axis, and drug toxicity [32] [33] [34] [35] [36] . In our cohort, patients who suffered acute hepatic decompensation had a 2-fold increased rate of mortality compared to those without and case fatality strongly correlated with degree of organ failure. However, even in patients with acute hepatic decompensation, lung disease remained the predominant cause of death, again suggesting that SARS-CoV-2 induced liver dysfunction may help propagate respiratory failure.

The large number of patients included in this study have allowed us to demonstrate for the first time that ALD is an independent risk factor for mortality following SARS-CoV-2 infection. The harmful use of alcohol is estimated to cause 3.3 million deaths every year, corresponding to nearly 6% of all deaths globally [37] . More than 200 life-limiting health conditions have been linked to alcohol consumption, with liver disease and cirrhosis having the highest alcoholattributable fraction [37] . Unfortunately, despite a concerted effort by the hepatology community to improve patient care and promote minimum unit pricing of alcohol [38] , the burden of ALD continues to rise in many areas of the world [39] [40] [41] . Of particular concern is the reported rise in alcohol consumption during the COVID-19 pandemic in parallel with deteriorating parameters of mental health [42] [43] [44] . Our data shows that ALD is a significant predictor of COVID-19 mortality, increasing the risk of death 1.8-fold. However, the patients with ALD in the current study did tend to have more severe underlying liver disease, for example the proportion without cirrhosis was only 6% in ALD patients compared to 62% in those with NAFLD (Supplementary   table 5 ). This is consistent with previous work showing that ALD often presents in the more advanced stages of disease [45] . Although liver disease stage was controlled for within multivariable analysis of the total CLD cohort, a separate analysis of risk factors for death restricted to patients with cirrhosis did not demonstrate any significant associations with liver disease aetiology (Supplementary table 6) . Further work is therefore required to decipher the significance of a direct, independent role of alcohol and ALD on the COVID-19 disease course.

The immunomodulating effects of excess alcohol are well established, predisposing to a range of viral and bacterial infections, [46] [47] [48] and to the development of acute respiratory distress syndrome (ARDS) in critically ill patients with sepsis [49] . However, the mechanisms through which alcohol consumption and ALD may impact on the pathogenesis of COVID-19 are not explained by the current study and require further exploration.

The strengths of the current study include the international nature of case submissions which gives a truly global perspective on the impact of SARS-CoV-2 infection in patients with CLD.

Clinician reporting also minimises the risk of misclassification of liver disease severity and outcomes although we accept that centralised definitions for cirrhosis and cause of death are lacking. In addition, comparing cases with a matched group of contemporaneous UK patients without CLD strengthens the associations between liver disease severity and mortality observed in the entire CLD cohort. However, our findings must be interpreted in the context of the study's J o u r n a l P r e -p r o o f potential limitations. Firstly, our registry data is vulnerable to reporting bias, possibly leading to over-representation of patients with more advanced liver disease or more severe COVID-19.

Notably, our registries contained predominantly hospitalised patients and therefore cannot comment in detail on the clinical course of COVID-19 in patients remaining in the community who either recovered or died without coming to the attention of secondary care. However, clinicians were encouraged to submit all consecutive cases from their centre and our reported rates of inpatient mortality in are comparable to those of previous studies [7, 8] . It is also reassuring that the registry includes a large proportion of patients without cirrhosis and with nonsevere COVID-19. Our registry data also may not capture cases in areas with limited availability of SARS-CoV-2 testing. However, the inclusion of patients exclusively with a laboratory proven diagnosis of SARS-CoV-2 infection does ensure standardization and guarantees that like-for-like comparisons are made between patient groups. Lastly, although we attempted to collect data on major covariables, there remains a possibility of unmeasured confounding not captured by our report form which was designed to allow rapid data entry during the peak of the pandemic. This includes the absence of surrogate biomarkers of inflammation such as full blood count and Creactive protein.

In conclusion, this international study across 130 centres and 29 countries reports on the largest cohort of patients with CLD and laboratory confirmed SARS-CoV-2 infection to date. We show for the first time that stage of liver disease is strongly associated with COVID-19 mortality and report high rates of hepatic decompensation and death in patients with cirrhosis. Furthermore, we show that alcohol aetiology of liver disease is an independent risk factor for death following SARS-CoV-2 infection even after controlling for liver disease severity. Plots show propensity-score matched analyses for risk of death for each CLD stage compared to non-CLD patients with SARS-CoV-2 infection. Variables selected for propensity score matching were age in years, interactions with age, sex, COPD, diabetes mellitus, and heart disease. Error bars represent Clopper-Pearson binomial confidence intervals at 95%. Identical analyses were performed for the total CLD cohort (Fig. 6A) and then restricted to UK CLD cases (Fig. 6B) . In the total CLD cohort, the risk of death for each disease stage was; CLD without cirrhosis -3.4% (95%CI -7.2-0.31%; p=0.248), CTP-A +2.0% (95%CI -6.2%-10.2%; p=0.631), CTP-B +20.0% (95%CI 8.8%-31.3%; p<0.001), CTP-C +38.1% (95%CI 27.1%-49.2%; p<0.001) (Fig. 6A) . In the UK CLD cohort, the risk of death for each disease stage was; CLD without cirrhosis +4.4% (95%CI -6.9%-15.8%; p=0.445), CTP-A +8.5% (95% CI -9.2-26.2; p=0.349), CTP-B +17.8% (95%CI 2.5-33.1%; p=0.023), and CTP-C +50.5% (95%CI 28.1%-72.8%; p=<0.001) (Fig. 6B) . 

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Burden of liver diseases in the world

Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies

Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Impact of chronic liver disease on outcomes of hospitalized patients with COVID 19: A multicentre United States experience

Clinical Characteristics and Outcomes of Coronavirus Disease

Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study

Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis

The REDCap consortium: Building an international community of software platform partners

High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry

An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study

Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis

Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure

Clerical Changes for Implementation of Adding Serum Sodium to the MELD Score. Organ Procurement and Transplantation Network

Methods for constructing and assessing propensity scores

Decreasing mortality among patients hospitalized with cirrhosis in the United States from

El-Serag HB. Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From

Influenza virus infection as precipitating event of acute-on-chronic liver failure

A prediction rule to identify low-risk patients with community-acquired pneumonia

Validity of pneumonia severity index and CURB-65 severity scoring systems in community acquired pneumonia in an Indian setting

Introduction to the ESMO COVID-19 Palliative Care Pathways n

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection

Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2

SARS-CoV-2 Infection and the Liver

Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis?

Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis

Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations

COVID-19 and Liver

Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK

Treating alcohol-related liver disease from a J o u r n a l P r e -p r o o f public health perspective

Rising Mortality From Alcohol-Associated Liver Disease in the United States in the 21st Century

Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis

Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder

Epidemic of COVID-19 in China and associated Psychological Problems

Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis?

Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide

Alcohol, Immunosuppression, and the Lung

Alcohol's Effect on Host Defense

Impact of Alcohol Abuse on the Adaptive Immune System

The authors wish to acknowledge all those who submitted cases to the registry (Supplementary